

Figure S1. The patient selection flow table.




Table S1. The treatment and outcomes of ovarian cancer patients with cancer-associated cerebral infarction.

Abbreviations: CI, cerebral infarction; ECOG-PS, Eastern Cooperative Oncology Group performance score; FIGO, International Federation of Gynecology and Obstetrics; CRS, cytoreductive surgery; IDS, interval debulking surgery; BSO, bilateral salpingo-oophorectomy; LAP, laparoscopy; TC, paclitaxel/carboplatin; TP, paclitaxel/cisplatin; C, carboplatin; 5-Fu, 5-Fluorouracil; IP, intraperitoneal; R0, complete cytoreduction; OS, overall survival; m, months.

C A S E	Age (years)	CI					CA125 before initial treatment (U/mL)	Surgery	Neoadju vant chemo (cycles of chemo, regimen)	Adjuvant chemo (cycles of chemo, regimen)	FIG O Sta ge	R0(0, no; 1, yes)	Standar d treatme nt (0, no; 1, yes)	Deat h (0, no; 1,yes)	OS (m)
		Time of CI (before treatme nt, 0; during treatme nt, 1)	Chief complaint at onset	ECO G-PS	D- dimer (mg/L) (Norma l, 0- 0.55)	CI lesions									
1	77	1	Unknown	1-2	2.50	Single	1000	IDS	20, unknow n	1, TC	IVB	0	0	1	18
2	72	0	Unknown	1-2	Unkno wn	Single	10681	IDS	2, TC	2, TC	IIIC	1	0	0	24
3	61	1	Hemiplegia	3-4	15.00	Multiple	11445	IDS	2, TC	8, TC	IIIC	0	1	1	12
4	61	0	Gait disturbance	1-2	2.40	Single	118	IDS	1, TC	7, TC	IIIC	1	1	0	11
5	58	0	Unknown	1-2	3.18	Multiple	12.63	CRS	0	4, TC	IC	1	1	0	49
6	37	1	Dysarthria; dizziness; vomiting	3-4	18.1	Multiple	1209	LAP	2, TC	0	IIIC	0	0	1	13
7	75	0		1-2	0.87	mono	126.2	CRS	0	6, 1TC and 5C	IIB	1	1	0	50

8	53	0	Dizziness	3-4	5.44	Multiple	1353	CRS	0	6, TC	IC	1	1	0	18
9	73	0	Unknown	1-2	1.78	Multiple	1574	IDS	3, TC	8, TC	IIIC	0	1	1	28
10	46	0	Dysarthria;	3-4	42.75	Multiple	1841	LAP	0	0	IVB	0	0	1	7
11	68	0	Dizziness; Transient loss of consciousness	1-2	4.23	Multiple	1953	IDS	3, TC	6, TC	IIIC	1	1	1	22
12	75	1	Dizziness; Hemiplegia	3-4	1.80	Multiple	198.4	CRS	0	1, TC	II	1	0	1	39
13	46	1	Lack of alertness; Dizziness;	3-4	16.93	Multiple	2080	IDS	3, TC	1, TC	IIIC	1	0	1	17
14	52	1	Dizziness	1-2	12.59	Multiple	2201	CRS	0	6, TC	IIIB	1	1	0	21
15	46	1	Dysarthria; Hemiplegia	3-4	14.90	Multiple	2273	CRS	0	3, TC	IIC	1	1	0	31
16	83	0	Dizziness	1-2	6.65	Multiple	253	CRS	0	0	IIIC	0	0	1	7
17	55	0	Dysarthria; Dizziness; Hemiplegia	3-4	6.65	Multiple	254	IDS	2, TC	6, TC	IV	0	1	0	6
18	59	0	Unknown	1-2	Unkno wn	Single	27.6	CRS	0	6, TC	IC	1	1	0	59
19	74	0	Dysarthria; Hemiplegia	1-2	4.80	Multiple	304	LAP	0	0	IIIc	0	0	1	6
20	59	0	Dizziness; Dysarthria	3-4	3.61	Multiple	385	IDS	1, TC	6, TC	IIIc	1	1	1	48
21	52	0	Dysarthria; Dizziness;	3-4	4.67	Multiple	417	Surgical staging	0	4, TC	IA	1	1	0	33
22	50	0	Hemiplegia	3-4	17.69	Multiple	447	IDS	2, TC	4, TC	IIB	1	1	0	5
23	70	0	Unknown	1-2	2.19	Single	598	BSO	0	1, TC	III	0	0	1	4

24	62	1	Dysarthria; Dizziness;	3-4	15.37	Multiple	62	CRS	0	0	IVB	0	0	1	1
25	62	0	Unknown	1-2	1.68	Single	635	CRS	0	10, TC	IIIC	0	1	1	39
26	51	0	Dizziness;	1-2	0.15	Single	71	IDS	1, 5-Fu (IP)	6, TC	IC	1	1	0	49
27	39	1	Dizziness; Dysarthria; Hemiplegia	3-4	2.97	Multiple	73	IDS	3, TC	3, TC	III	1	1	0	7
28	68	0	Dysarthria	1-2	1.71	Multiple	83.49	LAP	2, TC	0	IIIC	0	0	1	14
29	59	1	Dysarthria	3-4	0.75	Multiple	877	IDS	4, 3TC and 1TP	5, TC	IIIC	1	1	0	40
30	62	0	Dysarthria; vomiting	3-4	0.57	Multiple	99	CRS	0	8, docetaxel+ carboplatin	IIIC	1	1	1	57